Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy

Ziebart,Thomas; Ziebart,Johanna; Gauss,Leonie; Pabst,Andreas; Ackermann,Maximilian; Smeets,Ralf; Konerding,Moritz  A.; Walter,Christian

doi:10.3892/br.2013.145

Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy

Authors:
- Thomas Ziebart
- Johanna Ziebart
- Leonie Gauss
- Andreas Pabst
- Maximilian Ackermann
- Ralf Smeets
- Moritz A. Konerding
- Christian Walter
View Affiliations

Affiliations: Department of Maxillofacial Surgery, University Medical Center of Johannes Gutenberg University Mainz, D-55131 Mainz, Germany, Institute of Functional and Clinical Anatomy, University Medical Center of Johannes Gutenberg University Mainz, D-55131 Mainz, Germany, Department of Maxillofacial Surgery, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
Published online on: July 22, 2013 https://doi.org/10.3892/br.2013.145
Pages: 719-722

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bisphosphonates (BPs) are potent drugs, used in metastatic cancer-like prostate or breast carcinoma. In recent studies, besides reduced bone remodeling, influences on angiogenesis and neovascularization were reported. Since BPs have the tendency to accumulate in the bones, the biological effect of various nitrogen- and non-nitrogen BPs on endothelial progenitor cells (EPCs) that originated from bone marrow and mobilized under physiological and pathophysiological conditions, such as tumor neovascularization, was investigated. EPCs subsequent to 72‑h treatment with different concentrations of bisphosphonates comprised the non-nitrogen-containing BP clodronate and the nitrogen-containing BPs ibandronate, pamidronate and zoledronate. After incubation, biological activity was measured by using the migration boyden chamber assay and measurement of the colony-forming ability. Nitrogen-containing BPs inhibited the migration ability and differentiation of EPCs in a dose-dependent manner, as compared to the non-treated control groups. More specifically, the nitrogen-containing BP zoledronate significantly inhibited angiogenesis and neovascularization. Clodronate was less distinct on EPC function. To underline the importance of neovascularization in the context of tumor angiogenesis, EPC functions were significantly influenced in a dose-dependent manner by nitrogen-containing BPs. From these findings, we conclude that especially the nitrogen-containing BPs, such as zoledronate, are potential anticancer agents through the inhibition of neovascularization.

View Figures

View References

1	Neville-Webbe HL and Coleman RE: Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer. 46:1211–1222. 2010. View Article : Google Scholar : PubMed/NCBI
2	Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
3	Rogers MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 9:2643–2658. 2003. View Article : Google Scholar : PubMed/NCBI
4	Rogers MJ, Gordon S, Benford HL, et al: Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88:2961–2978. 2000. View Article : Google Scholar : PubMed/NCBI
5	Dunford JE, Thompson K, Coxon FP, et al: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 296:235–242. 2001.
6	Fisher JE, Rogers MJ, Halasy JM, et al: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA. 96:133–138. 1999. View Article : Google Scholar : PubMed/NCBI
7	Santini D, Vincenzi B, Avvisati G, et al: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 8:1080–1084. 2002.PubMed/NCBI
8	Yamada J, Tsuno NH, Kitayama J, et al: Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 151:115–120. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ziebart T, Pabst A, Klein MO, et al: Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig. 15:105–111. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
11	Rak JW, St Croix BD and Kerbel RS: Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 6:3–18. 1995. View Article : Google Scholar : PubMed/NCBI
12	Asahara T, Masuda H, Takahashi T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 85:221–228. 1999. View Article : Google Scholar
13	Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964–967. 1997. View Article : Google Scholar : PubMed/NCBI
14	Ziebart T, Yoon CH, Trepels T, et al: Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res. 103:1327–1334. 2008. View Article : Google Scholar : PubMed/NCBI
15	Urbich C, Heeschen C, Aicher A, et al: Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med. 11:206–213. 2005. View Article : Google Scholar : PubMed/NCBI
16	Efstathiou E, Bozas G, Kostakopoulos A, et al: Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology. 65:126–130. 2005. View Article : Google Scholar
17	Bertelli G, Heouaine A, Arena G, et al: Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol. 57:46–51. 2006. View Article : Google Scholar : PubMed/NCBI
18	Vogt U, Bielawski KP, Bosse U and Schlotter CM: Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 12:1109–1114. 2004.
19	Wood J, Bonjean K, Ruetz S, et al: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
20	Janic B and Arbab AS: The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. Sci World J. 10:1088–1099. 2010. View Article : Google Scholar : PubMed/NCBI
21	De Falco E, Porcelli D, Torella AR, et al: SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood. 104:3472–3482. 2004.PubMed/NCBI
22	Brunner M, Thurnher D, Heiduschka G, Grasl M, Brostjan C and Erovic BM: Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients. J Surg Oncol. 98:545–550. 2008. View Article : Google Scholar : PubMed/NCBI
23	Aicher A, Zeiher AM and Dimmeler S: Mobilizing endothelial progenitor cells. Hypertension. 45:321–325. 2005. View Article : Google Scholar : PubMed/NCBI
24	Hristov M, Erl W and Weber PC: Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 23:1185–1189. 2003. View Article : Google Scholar : PubMed/NCBI
25	Frith JC, Monkkonen J, Blackburn GM, Russell RG and Rogers MJ: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 12:1358–1367. 1997.PubMed/NCBI
26	Nogawa M, Yuasa T, Kimura S, et al: Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res. 15:1–9. 2005.PubMed/NCBI
27	Bifulco M: Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci. 77:1740–1749. 2005. View Article : Google Scholar : PubMed/NCBI
28	Crick DC, Andres DA and Waechter CJ: Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun. 237:483–487. 1997. View Article : Google Scholar : PubMed/NCBI